Immunotherapy of invasive fungal infection in hematopoietic stem cell transplant recipients by Lehrnbecher, Thomas et al.
“fonc-03-00017” — 2013/2/5 — 16:18 — page1—# 1
MINI REVIEW ARTICLE
published: 07 February 2013
doi: 10.3389/fonc.2013.00017
Immunotherapy of invasive fungal infection in
hematopoietic stem cell transplant recipients
Thomas Lehrnbecher*, Stanislaw Schmidt, LarsTramsen andThomas Klingebiel
Pediatric Hematology and Oncology, Children’s Hospital, Johann Wolfgang Goethe University, Frankfurt, Germany
Edited by:
Crystal Mackall, National Cancer
Institute, USA
Reviewed by:
Roland Meisel, University Hospital
Düsseldorf, Germany




Hematology and Oncology, Children’s




Despite the availability of new antifungal compounds, invasive fungal infection remains a
signiﬁcant cause of morbidity and mortality in children and adults undergoing allogeneic
hematopoietic stem cell transplantation (HSCT). Allogeneic HSCT recipients suffer from
a long lasting defect of different arms of the immune system, which increases the risk
for and deteriorates the prognosis of invasive fungal infections. In turn, advances in
understanding these immune deﬁcits have resulted in promising strategies to enhance
or restore critical immune functions in allogeneic HSCT recipients. Potential approaches
include the administration of granulocytes, since neutropenia is the single most important
risk factor for invasive fungal infection, and preliminary clinical results suggest a beneﬁt
of adoptively transferred donor-derived antifungalT cells. In vitro data and animal studies
demonstrate an antifungal effect of natural killer cells, but clinical data are lacking to date.
This review summarizes and critically discusses the available data of immunotherapeutic
strategies in allogeneic HSCT recipients suffering from invasive fungal infection.
Keywords: invasive fungal infection, allogeneic hematopoietic stem cell transplantation, immunotherapy, granulo-
cyte,T cell, natural killer cell
Invasive fungal infection remains a signiﬁcant cause of morbid-
ity and mortality in children and adults undergoing allogeneic
hematopoietic stem cell transplantation (HSCT). The most com-
mon fungal pathogens identiﬁed in this patient population are
Candida spp. andinparticularAspergillus spp.;inthelattergroup,
the majority of invasive infections are due to A. fumigatus, fol-
lowed by A. ﬂavus, A. niger, and A. versicolor (Morgan etal.,
2005; Pagano etal., 2007). In addition, recent studies report on
an increasing incidence of infections due to Mucormycetes which
areusuallycausedbythegeneraRhizopus,Rhizomucor,Mucor,and
Lichtheimia (Cuenca-Estrella etal., 2009). Although the deﬁnitive
diagnosis of invasive fungal infection in the population of allo-
geneic HSCT recipients is difﬁcult to establish, two recent studies
report on an overall incidence of 3.4 and 7.8% of proven and
probable invasive fungal infections, respectively; however, it is
important to note that a considerable variability across institu-
tions has been reported,and incidence rates may vary between 0.9
and 13.2% (Dvorak etal., 2005; Pagano etal., 2007; Kontoyiannis
etal.,2010).
Despite the availability of new antifungal compounds such
as broad-spectrum triazoles or the new class of echinocandins,
morbidity and mortality of invasive fungal infections are still
unacceptably high. In this respect, recent analyses report on mor-
tality rates between 36% (combined analysis for autologous and
allogeneic HSCT) and 67% (analysis for allogeneic HSCT from
unrelated donors) due to invasive aspergillosis (Mikulska etal.,
2009; Neofytos etal., 2009). In patients with mucormycosis, 1-
year mortality exceeded 70% (Dvorak etal., 2005; Pagano etal.,
2007; Kontoyiannis etal., 2010).
Although pharmacological prophylactic measures (e.g., the
institution of antifungal prophylaxis with posaconazole) and
improved therapeutic approaches have decreased morbidity and
mortality of invasive fungal infections, experts agree that the
integrity of host defenses remains the mainstay of defense. Allo-
geneic HSCT is characterized by a subsequent period of immun-
odeﬁciency. The duration and severity of these defects of host
immunity vary due to multiple factors, such as graft manipula-
tion and choice of graft type (donor and source), intensity of
conditioning, in vivo T cell depletion, and choice, duration, and
intensity of pharmacological graft-versus-host-disease (GvHD)
prophylaxis and treatment. The conditioning chemotherapeutic
regimen, which often includes radiation, results in the disruption
of mucosal barriers and eradicates the recipient’s neutrophils and
lymphoid tissue. Whereas mucositis and neutropenia resolve over
the ﬁrst weeks after transplantation, the impairment of cellular
immunity may persist over a prolonged period of time. After the
recipient’simmunesystemisrestored,theriskortheoccurrenceof
GvHD may further induce immunologic compromises. It is well
known that the impairment of these arms of the immune system
signiﬁcantly increases the risk for and deteriorates the outcome
of invasive fungal infection. In turn, advances in understand-
ing of these immune deﬁcits in the allogeneic HSCT recipient
have resulted in promising strategies to enhance or restore critical
immune functions in order to combat invasive fungal infections,
which will be critically discussed in this article.
THE IMPACT OF GRANULOCYTES IN INVASIVE FUNGAL
INFECTION: IS THERE A BENEFIT OF GRANULOCYTE
TRANSFUSION?
Neutropenia is the single most important risk factor for invasive
fungalinfection,withthehighestriskinpatientswithsevere(abso-
lute neutrophil count,ANC < 500/μl) and prolonged (>10 days)
neutropenia. In the transplant setting, about one-third of inva-
sive fungal infections occur in the pre-engraftment period (Bow,
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2009); notably, the time to neutrophil engraftment depends on a
number of factors such as conditioning regimen,stem cell source,
andprocessingof thestemcellproduct.Therefore,thetransfusion
of granulocytes from healthy individuals has been considered as
an option for adjunctive immunotherapy in patients with neu-
tropenia or impaired neutrophil function who are at high risk
for or suffer from invasive fungal infection. A retrospective case–
controlstudyin29cancerpatientssufferingfromCandida species
bloodstream infections suggested that therapy with granulocyte
transfusionswasassociatedwithbetterthanexpectedsurvivalrates
(Safdar etal., 2004). These data corroborated smaller case series
in neutropenic children and adults with various severe infectious
complications including invasive fungal infection (Mousset etal.,
2005; Grigull etal., 2006; Atay etal., 2011). Although the studies
described granulocyte transfusions as safe, fever and chills may
be seen in up to 20% of transfusions, and pulmonary reactions
(acuterespiratorydistresssyndrome,ARDS)andhumanleukocyte
antigen (HLA) alloimmunization have been reported as potential
major complications (O’Donghaile etal., 2012). In addition, a
randomized phase III study evaluating the effect of granulocyte
transfusions in 74 neutropenic patients, most of them after allo-
geneic HSCT (n = 39), failed to demonstrate a signiﬁcant beneﬁt
of this approach (Seidel etal., 2008). The administration of gran-
ulocytes did not improve survival rates until day 100 in patients
with fungal (n = 55) and other infections. The authors attributed
the lack of efﬁcacy to procedural obstacles, which is supported
by the observation that neutrophil reconstitution was equal in
the treatment and control arm indicating that the granulocyte
transfusions administered at the schedule and dose used were not
sufﬁcienttoacceleratealastingperipheralbloodneutrophilrecon-
stitution. Therefore, the results of large prospective randomized
trials assessing the effect of high dose granulocyte transfusion in
neutropenic patients, such as the ring study (NCT00627393) are
urgently needed to prove or refute the empirical evidence of the
beneﬁt of granulocyte transfusion in this setting.
T CELLS AND INVASIVE FUNGAL INFECTION
Incontrasttoarelativelyrapidrecoveryofcellsofinnateimmunity
suchasgranulocytes,boththeabsolutelevelsandfunctionofBand
T lymphocytes remain abnormal for many months (Eyrich etal.,
2001; Peggs and Mackinnon, 2004). T cells are known to possess
somegraft-versus-malignancyeffectandtoplayanimportantrole
inthedefenseagainstviralpathogens(Baderetal.,2004;Peggsand
Mackinnon, 2004). However, there is a growing body of evidence
suggestingthatadaptiveimmunity,inparticularCD4+ Tlympho-
cytes,hasanimportantfunctioninthehostresponseagainstfungi.
For example,non-neutropenic patients with advanced AIDS have
a high risk for invasive aspergillosis (Denning,1998). In addition,
in the transplant setting, the median time of invasive aspergillo-
sis,invasivecandidiasis,andzygomycosisis82days(range3–6542
days), 77 days (range 0–2219 days), and 173 days (range 7–2254
days) after HSCT, respectively, a time, when neutropenia and
mucositishavegenerallyresolved,butadaptiveimmuneresponses
are still hampered (Hamza etal., 2004; Neofytos etal., 2009). An
early study demonstrated that the presence of CD4+ T lympho-
cytes, which secrete interferon-gamma (IFN-γ) upon stimulation
with A. fumigatus antigens indicatingaTh e l p e rt y p e1( T H1) cell
response,correlatedwithafavorableoutcome(Hebartetal.,2002).
It has also been shown that for up to 1 year after HSCT,transplant
recipients have a signiﬁcantly reduced number of functionally
active anti-Aspergillus T cells compared to healthy controls, and
lymphopenia is associated with a higher risk of death of trans-
plant recipients with invasive fungal infection (Beck etal., 2008;
Mikulska etal., 2009).These data provide the rationale of adop-
tively transferring in vitro manufactured anti-Aspergillus Tc e l l s
for prevention or for treatment of Aspergillus infections. In the
ﬁrstclinicaltrial,tenhaploidenticaltransplantrecipientswithevi-
denceof invasiveaspergillosis(e.g.,pulmonaryinﬁltrates,positive
galactomannan test) received anti-Aspergillus T cells in the dose
range of 1 × 105 to 1 × 106 per kg body weight between 17 and 37
daysaftertransplantation(Perruccioetal.,2005).Inall10patients,
galactomannan positivity disappeared within 6 weeks of infusion
of anti-Aspergillus T cells whereas it persisted in the 13 controls
not receiving immunotherapy for as long as monitored. In addi-
tion, 9 out of the 10 patients who had received anti-Aspergillus T
cells cleared invasive aspergillosis, whereas this was seen in only
7 out of the 13 controls. Anti-Aspergillus T cell clones were pre-
pared by using heat-inactivated conidia for stimulation followed
by limiting dilution which involved complex cell manipulation.
Consequently, there was much interest in improving the tech-
niques for the clinical scale-generation of anti-Aspergillus T cells.
Tramsen etal. (2009) used an Aspergillus extract for stimulation;
pathogen-speciﬁc antifungal cells were selected by means of the
IFN-γ secretion assay and expanded. Out of a total of 1.1 × 109
white blood cells from a leukapheresis product,a median number
of2×107CD4+Tcellswereobtainedwithin13days.Thecultured
anti-Aspergillus cells exhibited almost exclusively a memory acti-
vated TH cell phenotype. Upon re-stimulation,the generated cells
produced IFN-γ, but not interleukin (IL)-4 or IL-10, indicating a
TH1 population. In addition,the cells were not end-differentiated
T cells, since they proliferated upon re-stimulation. Interestingly,
the functionally active anti-Aspergillus TH1 cells elicited limited
cross-reactivity with other Aspergillus species and fungi (Beck
etal., 2006). As compared to unselected CD4+ cells, the gener-
atedanti-AspergillusTcellsexhibitedreducedalloreactivityinvitro
(Tramsen etal., 2009).
Recently, a simple, robust and clinically applicable procedure
of generating anti-Aspergillus T cells was reported using an envi-
ronmental strain of A. fumigatus and materials and reagents for
clinical manufacture (Gaundar etal., 2012). In this protocol, cells
were expanded with a cocktail of IL-2, IL-7, and IL-15, which
resulted in a 30-fold increase in cell numbers over 21 days of
culture. Generated cells were predominantly effector and central
memory CD4+ T cells, which produced TH1 and TH17 cytokines
and expanded upon re-stimulation.
Although most groups have employed lysates from Aspergillus
isolates for the generation of protecting anti-Aspergillus Tc e l l s
(Perruccio etal., 2005; Tramsen etal., 2009; Khanna etal., 2011;
Gaundar etal., 2012), the use of antigen extracts may be con-
sidered problematic from a regulatory standpoint. On the other
hand,whereas the immunogenic antigens of viruses such as aden-
ovirus, cytomegalovirus (CMV) or Epstein–Barr virus (EBV) are
well described, the antigenic properties of A. fumigatus are rather
complex and only a few of the hundreds of (glyco)proteins of
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protective TH cell responses in mice and humans (Bozza etal.,
2009). In addition, an immunodominant epitope derived from
A. fumigatus cell wall glucanase Crf1, restricted to three common
majorhistocompatibilitycomplexclassIIalleles,HLA-DRB1*03,-
04,and-13,hasbeenidentiﬁedwhichinducescross-reactiveCD4+
TH1 immunity not only against A. fumigatus, but also against C.
albicans (Stuehler etal., 2011). However, beside the restriction to
donors with certain HLA-alleles, it is important to note that the
Aspergilluscellwallisahighlydynamicstructurewiththeabilityto
adapt to different environments. Depending on the speciﬁc envi-
ronment, each of the fungal morphotypes may exhibit different
biological features, which in turn, can inﬂuence the pathogenic-
ity of the pathogen and may result in the differential expression
of antigens on its surface. Therefore, the fungal pathogen could
easily escape from adoptive immunotherapy using antifungal T
cells recognizing only a single antigen,whereas an approach using
a fungal extract which includes multiple antigens for generating
antifungal T cells might decrease this risk. To this end,the speciﬁc
advantages and limitations of the use of a lysate from Aspergillus
isolatesandofsingleormultipleantigenshavetobeevaluated,and
further studies will show which will be the most feasible approach
in the clinical setting.
Unfortunately, in the clinical setting, no distinct fungal
pathogen can be isolated and characterized in the majority of
patients with a suspected invasive fungal infection; this, how-
ever, is considered to be a prerequisite for the determination of
the antigen in order to generate pathogen-speciﬁc T cells. In addi-
tion, imaging studies such as computed tomography (CT) scan
or the detection of a fungal antigen such as galactomannan, does
not prove an infection due to a speciﬁc fungal pathogen. Lastly, a
considerablenumberofpatientssufferfromco-infectionwithsev-
eral species or genera of fungi. Therefore, similar to the approach
in antiviral immunotherapy using T cell populations that target
CMV, EBV, and adenovirus simultaneously (Hanley etal., 2009),
the generation of multi-speciﬁc T cells which target a variety
of different clinically important fungi such as Aspergillus spp.,
Candida spp., and Mucormycetes would be of major advantage.
We recently reported on an approach of generating multi-speciﬁc
human antifungal T cells after simultaneous stimulation with cel-
lular extracts of A. fumigatus, C. albicans, and Rhizopus oryzae
(Tramsen etal., 2013a). These generated cells consisted of acti-
vated memory TH1 cells and reproducibly responded with IFN-γ
production to a broad-spectrum of medically important fungal
pathogens, such as A. fumigatus, A. niger, Penicillium chryso-
genum, C. albicans, C. tropicalis, M. circinelloides, Rhizomucor
pusillus, Rhizopus oryzae, Rhizopus microsporus, and Rhizopus
microsporus-oligosporus. Upon re-stimulation, the generated T
cells proliferated and enhanced antifungal activity of phagocytes,
and showed reduced alloreactivity as compared to the original cell
fraction. The ultimate goal would be to generate antifungal T cells
against all medically important fungi.
Various antifungal agents have been shown to inﬂuence the
function of the host immune response. For instance, early studies
demonstrated that itraconazole suppresses random movement
and chemotaxis of neutrophils (Vuddhakul etal.,1990),and lipo-
somal amphotericin B and amphotericin B-deoxycholate show
different immunoregulatory effects on human peripheral blood
mononuclear cells (Reyes etal., 2000). In addition, liposomal
amphotericin B suppresses speciﬁc activity of cytotoxic CD8+ T
cells in the setting of murine listeriosis (Kretschmar etal., 2001).
In contrast, we recently reported that various concentrations
of commonly used antifungal compounds such as amphotericin
B-deoxycholate,liposomalamphotericinB,ﬂuconazole,voricona-
zole,posaconazole,andcaspofungindidnotsigniﬁcantlyinﬂuence
the secretion of IFN-γ and tumor necrosis factor-alpha (TNF-α)
by human anti-Aspergillus and human anti-Candida TH1c e l l s
(Tramsenetal.,2013b).Theproliferationof thesecellswasslightly
decreased by posaconazole at high concentrations only, which,
however, did not reach statistical signiﬁcance. These data suggest
that antifungal T cells can be safely administered together with
commonly used antifungal compounds.
ANTIFUNGAL ACTIVITY OF NATURAL KILLER CELLS
Since natural killer (NK) cells are able to kill tumor cells
in vitro, there is increasing interest in using NK cells as adop-
tive immunotherapy against malignancies in HSCT recipients. In
contrasttoadoptivelytransferreddonor-derivedTcells,whichare
associatedwiththeriskofGvHD,NKcellsareusuallywelltolerated
and may even mitigate GvHD (Passweg etal., 2006). In addition
totheantitumoreffect,NKcellsexhibitcytotoxicityagainstvirus-
infected cells and activity against bacteria such as Staphylococcus
aureusandagainstvariousparasites(Biron,1997;Liekeetal.,2004;
Small etal., 2008). There is also growing evidence of in vitro and
animal studies that NK cells play an important role in the host
response against fungal pathogens. For example, in vitro data
demonstrate that NK cells are able to damage Aspergillus spp. and
Rhizopus oryzae (Bouzani etal., 2011; Schmidt etal., 2011, 2012).
Importantly, hyphae of both fungi are damaged by both freshly
isolated and IL-2 pre-stimulated NK cells,whereas conidia are not
affected (Bouzani etal., 2011; Schmidt etal., 2011, 2012). The in
vitro data on the damage of Aspergillus spp. by NK cells are sup-
ported by animal studies (Morrison etal., 2003; Park etal., 2009).
For example, in neutropenic mice suffering from pulmonary
aspergillosis, the depletion of NK cells by antibodies resulted in
agreaterthantwofoldincreaseinmortalityandmarkedlyreduced
clearance of the pathogen from the lungs (Morrison etal., 2003).
Similarly, depletion of NK cells reduced lung IFN-γ levels and
subsequently increased fungal load, whereas the transfer of acti-
vated NK cells from wild-type, but not from IFN-γ-deﬁcient
mice resulted in greater pathogen clearance from the lungs,which
supports the importance of functionally active NK cells in the
antifungalhostresponse(Parketal.,2009). If furtherstudieseval-
uating the effect and side effects of adoptively transferred NK cells
to an immunocompromised host with invasive fungal infection
will demonstrate a beneﬁt, NK cells might become an interesting
tool in immunotherapeutic antifungal strategies.
CONCLUDING REMARKS
Invasive fungal infections, in particular infections due to
Aspergillus, Candida, and Mucormycetes, are still a major
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causeofmorbidityandmortalityinHSCTpatients.Thesepatients
suffer from long lasting defects of the host immune response,
and despite the availability of new antifungal compounds, mor-
tality in this patient population is unacceptably high. Over the last
decades, our knowledge of the immunopathogenesis of invasive
fungal infections has greatly advanced, and the role of differ-
ent arms of host immunity, such as the roles of phagocytes,
T cells and NK cells have been elucidated. Data of in vitro
experiments and animal studies have provided us with impor-
tant information to augment host immunity, which resulted
in growing interest in the clinical application of immunother-
apeutic approaches in HSCT recipients suffering from invasive
fungal infections. Although further information obtained from
preclinical in vivo models is crucial, only clinical trials will ulti-
mately demonstrate the impact of speciﬁc cell populations in
the prevention or treatment of invasive fungal infections in the
transplant recipient. These clinical trials have to address impor-
tant questions such timing of intervention, type and dosing
of adoptively transferred cells, and eligible patients. The latter
most likely depends on the host’s unique genetic background,
which might have important impact on susceptibility, clinical
course, and outcome of invasive fungal infections. In addition,
it is important to note that patients suffering from invasive fun-
gal infection are a heterogenous population, not only regarding
the underlying pathogen, but also regarding affected organs as
well as antifungal pre-treatment. Therefore, it will be difﬁcult to
prove a clinical beneﬁt of a speciﬁc immunotherapeutic strat-
egy in a sufﬁciently powered number of patients. In order to
design meaningful clinical trials, international, multi-center col-
laboration is required, which hopefully will improve the outcome
in immunocompromised patients suffering from invasive fungal
infection.
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